Gilead — Piv­otal Covid-19 study of remde­sivir ‘met its pri­ma­ry end­point,' is emer­gency au­tho­riza­tion next?

6 years ago
R&D
Coronavirus

Full steam ahead, Pfiz­er goes bar­gain hunt­ing in an age of coro­n­avirus — with a spe­cial fo­cus on can­cer and rare ...

6 years ago
Bioregnum
R&D

FDA, EU au­thor­i­ties up­date guid­ance on clin­i­cal tri­als dur­ing Covid-19

6 years ago
FDA+
Coronavirus

In the heart of Texas, the AveX­is crew gath­ers for an­oth­er go at gene ther­a­py with $30M and a pow­er­house aca­d­e­m­ic ...

6 years ago
Financing
Startups

Sue Desmond-Hell­mann joins the mar­quee crowd of bio­phar­ma ex­perts at GV boot­ing up a new gen­er­a­tion of drug hunters

6 years ago
People

Hav­ing sold its cor­po­rate self, Toca­gen auc­tions off sci­en­tif­ic plat­form to San Diego biotech

6 years ago
Deals
Cell/Gene Tx

Covid-19 roundup: J&J part­ners with Catal­ent on 1B dose vac­cine goal; BioN­Tech, Pfiz­er be­gin mR­NA vac­cine tri­al in ...

6 years ago
Coronavirus

Third Rock-backed star­tup's blood test can sniff out can­cer in pa­tients with no his­to­ry of dis­ease

6 years ago
Financing
Startups

Blue­print stum­bles in PhI­II GIST tri­al, send­ing stock slid­ing, but an­a­lysts preach cau­tion

6 years ago
R&D

Astel­las part­ners with In­sil­i­co, Har­vard; Zam­bon gets FDA's fast track sta­tus for lung drug

6 years ago
News Briefing

Amid string of splashy pan­dem­ic IPOs, ADC re­turns for its mil­lions

6 years ago
Financing

Bank­ing on hope, swayed by hype? Hy­drox­y­chloro­quine in the time of Covid-19

6 years ago
FDA+
Coronavirus

Ver­tex's cys­tic fi­bro­sis drugs work, but they're too ex­pen­sive, ICER finds

6 years ago
Pharma
FDA+

Covid-19 roundup: Re­searchers claim tri­al suc­cess for Roche's Actem­ra as Alex­ion jumps in; Pfiz­er gam­bling $500M on ...

6 years ago
Coronavirus

Gilead fires back in on­go­ing bat­tle with HHS, su­ing the gov­ern­ment for ‘se­cret­ly’ ob­tain­ing patents

6 years ago
R&D

With ex­pan­sive Covid-19 clin­i­cal plan in full gear, Ox­ford team re­ports pos­i­tive an­i­mal da­ta on ade­n­ovirus-based ...

6 years ago
Coronavirus

Weeks af­ter FDA de­lay, Roche, PTC un­veil an­oth­er batch of pos­i­tive ris­diplam da­ta in se­vere SMA pa­tients

6 years ago
R&D
FDA+

#AACR20 roundup: Tecen­triq/Xtan­di com­bo fails to show OS ben­e­fit, halt­ing Roche's PD-L1 push in­to prostate can­cer

6 years ago
R&D

Re­gen­eron/Sanofi PD-1 tri­al halt­ed for sig­nif­i­cant ef­fi­ca­cy; Avadel soars on pos­i­tive nar­colep­sy da­ta

6 years ago
News Briefing

Boehringer In­gel­heim VC backs plan to send GMO bac­te­ria af­ter tu­mors

6 years ago
Financing
Startups

An on­col­o­gy up­start with some deep-pock­et VC con­nec­tions has a uni­corn-sized ven­ture round to back the pipeline

6 years ago
Financing
Startups

#AACR20: Ear­ly da­ta sug­gest No­var­tis' In­cyte-dis­cov­ered MET in­hibitor helps lung can­cer pa­tients with brain le­sions

6 years ago
R&D

Ax­some shares rock­et up on a sur­prise win for late-stage Alzheimer’s ag­i­ta­tion study — but this is no easy layup

6 years ago
R&D

Covid-19 roundup: Sanofi & Re­gen­eron de­liv­er dis­ap­point­ing news on IL-6; Alex Azar ru­mors are swirling at HHS

6 years ago
R&D
Coronavirus
First page Previous page 832833834835836837838 Next page Last page
A service from the Financial Times